Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos Pedraz

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Extracellular Vesicles and Circulating Nucleic Acids|December 19, 2024
Defining the landscape of circRNAs in non-small cell lung cancer and their potential as liquid biopsy biomarkers: a complete review including current methodsCarlos Pedraz-Valdunciel, Rafael Rosell
The Lancet. Oncology|October 9, 2019
Are neutralising anti-VEGF or VEGFR2 antibodies necessary in the treatment of EGFR-mutated non-small-cell lung cancer?Rafael Rosell, Carlos Pedraz-Valdunciel
JTO Clinical and Research Reports|October 16, 2023
Lung Cancer Organoids as Avatars of Patients With Lung Cancer in the Prediction of Therapeutic ResponseRafael Rosell, Carlos Pedraz-Valdunciel
Nature Cancer|February 5, 2022
KRAS inhibitors, approvedRafael Rosell, Andrés Aguilar, Carlos Pedraz, et al.
Nature Cancer|April 5, 2022
Author Correction: KRAS inhibitors, approvedRafael Rosell, Andrés Aguilar, Carlos Pedraz, et al.
Expert Opinion on Biological Therapy|February 15, 2019
Biological therapies in lung cancer treatment: using our immune system as an ally to defeat the malignancyMartyna Filipska, Carlos Pedraz-Valdunciel, Imane Chaib, et al.
Molecular Cancer|January 24, 2024
Pangaea Oncology, Dexeus University Hospital: bridging preclinical and clinical researchMaría González-Cao, Carlos Pedraz, Miguel Ángel Molina-Vila, et al.
Expert Opinion on Investigational Drugs|February 19, 2024
Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusionsRafael Rosell, Carlos Pedraz-Valdunciel, Anisha Jain, et al.
JTO Clinical and Research Reports|January 1, 2024
Brief Report: circRUNX1 as Potential Biomarker for Cancer Recurrence in EGFR Mutation-Positive Surgically Resected NSCLCCarlos Pedraz-Valdunciel, Masaoki Ito, Stavros Giannoukakos, et al.
British Journal of Cancer|August 10, 2021
Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunitiesRafael Rosell, Andrés Felipe Cardona, Oscar Arrieta, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Extracellular Vesicles and Circulating Nucleic Acids|December 19, 2024
Defining the landscape of circRNAs in non-small cell lung cancer and their potential as liquid biopsy biomarkers: a complete review including current methodsCarlos Pedraz-Valdunciel, Rafael Rosell
The Lancet. Oncology|October 9, 2019
Are neutralising anti-VEGF or VEGFR2 antibodies necessary in the treatment of EGFR-mutated non-small-cell lung cancer?Rafael Rosell, Carlos Pedraz-Valdunciel
JTO Clinical and Research Reports|October 16, 2023
Lung Cancer Organoids as Avatars of Patients With Lung Cancer in the Prediction of Therapeutic ResponseRafael Rosell, Carlos Pedraz-Valdunciel
Nature Cancer|February 5, 2022
KRAS inhibitors, approvedRafael Rosell, Andrés Aguilar, Carlos Pedraz, et al.
Nature Cancer|April 5, 2022
Author Correction: KRAS inhibitors, approvedRafael Rosell, Andrés Aguilar, Carlos Pedraz, et al.
Expert Opinion on Biological Therapy|February 15, 2019
Biological therapies in lung cancer treatment: using our immune system as an ally to defeat the malignancyMartyna Filipska, Carlos Pedraz-Valdunciel, Imane Chaib, et al.
Molecular Cancer|January 24, 2024
Pangaea Oncology, Dexeus University Hospital: bridging preclinical and clinical researchMaría González-Cao, Carlos Pedraz, Miguel Ángel Molina-Vila, et al.
Expert Opinion on Investigational Drugs|February 19, 2024
Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusionsRafael Rosell, Carlos Pedraz-Valdunciel, Anisha Jain, et al.
JTO Clinical and Research Reports|January 1, 2024
Brief Report: circRUNX1 as Potential Biomarker for Cancer Recurrence in EGFR Mutation-Positive Surgically Resected NSCLCCarlos Pedraz-Valdunciel, Masaoki Ito, Stavros Giannoukakos, et al.
British Journal of Cancer|August 10, 2021
Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunitiesRafael Rosell, Andrés Felipe Cardona, Oscar Arrieta, et al.
Pageof 3